Advances in Cancer Immunology and Immunotherapy

Roman Anton

Authors

Roman Anton

Keywords:

cancer, immunology, Immunotherapy, CAR T, antibodies, ADC, CDC, ADP, bias, review

Abstract

Abstract not found

Downloads

How to Cite

Advances in Cancer Immunology and Immunotherapy. (2018). Global Journal of Medical Research, 18(F2), 33-56. https://medicalresearchjournal.org/index.php/GJMR/article/view/1563

Download Citation

References

Jacques Miller, Michel Sadelain (2015) The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy. 27(4), 439-449.

Padmanee Sharma, Klaus Wagner, Jedd Wolchok, James Allison (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. 11(11), 805-812.

Megan Mcnamara, Smita Nair, Eda Holl (2015) RNA-Based Vaccines in Cancer Immunotherapy. 2015, 1-9.

A Patrick, F Hodi, H Kaufman, J Wigginton, J Wolchok (2017) Combination immunotherapy: a road map. 5(16), 1-15.

Nature (2012) Nature Reviews -Focus on Tumor Immunology and Immunotherapy; Table of Contents (publications herein). 12(4).

A Sukari, M Nagasaka, A Al-Hadidi, L Lum (2016) Cancer Immunology and Immunotherapy. 36(11), 5593-5606.

Y Yang (2015) Cancer immunotherapy: harnessing the immune system to battle cancer. 125(9), 3335-3337.

Cell (2015) Cancer, Immunity, and Immunotherapy -Reviews from Cancer Cell and Trends in Immunology.

C Voena, R Chiarle (2016) Advances in cancer immunology and cancer immunotherapy. 21(114), 125-133.

Kimberly Miller, Rebecca Siegel, Chun Lin, Angela Mariotto, Joan Kramer, Julia Rowland, Kevin Stein, Rick Alteri, Ahmedin Jemal (2016) Cancer treatment and survivorship statistics, 2016. 66(4), 271-289.

(2018) FDA drug approvals.

Ksp (2017) Global Cancer Immunotherapy Market Analysis & Forecast to.

P Taylor (2017) The top 15 best-selling cancer drugs in 2022. 1-16.

J Scannell, J Bosley (2016) When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis. 11(2), 1-21.

James March (1991) Exploration and Exploitation in Organizational Learning. 2(1), 71-87.

Abraham Carmeli, Meyrav Halevi (2009) How top management team behavioral integration and behavioral complexity enable organizational ambidexterity: The moderating role of contextual ambidexterity. 20(2), 207-218.

Ramana Nanda (2016) Financing high-potential entrepreneurship. 1(1).

R Choi (2015) Increasing Transparency of Clinical Trial Data in the United States and the European Union. 14(3), 520-548.

G Forni (2015) Vaccines for tumor prevention: a pipe dream?. 9(6), 600-608.

G Stevenson (2014) Three major uncertainties in the antibody therapy of cancer. 99(10), 1538-1546.

Jacques Descotes (2009) Immunotoxicity of monoclonal antibodies. 1(2), 104-111.

Frank Brennan, Laura Morton, Sebastian Spindeldreher, Andrea Kiessling, Roy Allenspach, Adam Hey, Patrick Müller, Werner Frings, Jennifer Sims (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. 2(3), 233-255.

D Lee (2014) Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195.. 126(8), 1048-1048.

A Mirsoian (2014) Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. 211(12), 2373.

Chunpeng Yang, Xinyu Gao, Rui Gong (2017) Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics. 8(1860), 1-14.

Richard Larson, Navid Ghaffarzadegan, Yi Xue (2015) Too Many PhD Graduates or Too Few Academic Job Openings: The Basic Reproductive Number R₀ in Academia. 31(6), 745-750.

Bruce Alberts, Marc Kirschner, Shirley Tilghman, Harold Varmus (2014) Rescuing US biomedical research from its systemic flaws. 111(16), 5773-5777.

Troy Shinbrot (1999) Exploitation of junior scientists must end. 399(6736), 521-521.

Saskia Meyer, Jeanette Leusen, Peter Boross (2014) Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. 6(5), 1133-1144.

Gregory Moore, Hsing Chen, Sher Karki, Greg Lazar (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. 2(2), 181-189.

E Walter (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. 333(16), 1038-1044.

Cri (2018) Timeline of Cancer Immunotherapy.

Nina Pilat, Mohamed Sayegh, Thomas Wekerle (2011) Costimulatory pathways in transplantation. 23(4), 293-303.

Steven Rosenberg, Nicholas Restifo, James Yang, Richard Morgan, Mark Dudley (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. 8(4), 299-308.

William Ho, Joseph Blattman, Michelle Dossett, Cassian Yee, Philip Greenberg (2003) Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction. 3(5), 431-437.

Michael Kalos, Carl June (2014) Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology. 39(1), 49-60.

M Wang, B Yin, H Wang, R Wang (2014) Current advances in T-cell-based cancer immunotherapy. 6(12), 1265-1278.

S Rosenberg, N Restifo (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. 80(6230), 62-68.

Y Kong, J Zhang, D Claxton, W Ehmann, W Rybka, L Zhu, H Zeng, T Schell, H Zheng (2015) PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. 5(7), e330-e330.

Olle Ringdén, Helen Karlsson, Richard Olsson, Brigitta Omazic, Michael Uhlin (2009) The allogeneic graft‐versus‐cancer effect. 147(5), 614-633.

Giao Phan, Steven Rosenberg (2013) Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy. 20(4), 289-297.

S Lindegaard (2010) The open innovation revolution -Esssentials, roadblocks, and leadership skills. 8.

H Chesbrough (2003) Open Innovation: the new imperative for creating and profiting from technology.

Y Jiang, Y Li, B Zhu (2015) T-cell exhaustion in the tumor microenvironment. 6(6), e1792-e1792.

H Symons (2008) The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. 14(5), 28.

Julie Curtsinger, Matthew Mescher (2016) Inflammatory cytokines as a third signal for T cell activation. 22(3), 333-340.

A Corthay (2006) A Three‐cell Model for Activation of Naïve T Helper Cells. 64(2), 93-96.

Vita Golubovskaya, Lijun Wu (2016) Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. 8(3), 36.

G Chunqing, M Manjili, R John, S Devanand, B Paul, X Wang (2014) Therapeutic Cancer Vaccines. 119, 421-475.

Giorgio Parmiani, Vincenzo Russo, Cristina Maccalli, Danilo Parolini, Nathalie Rizzo, Michele Maio (2015) Peptide-based vaccines for cancer therapy. 10(11), 3175-3178.

F González, A Gleisner, F Falcón-Beas, F Osorio, N López, F Salazar-Onfray (2014) Tumor cell lysates as immunogenic sources for cancer vaccine design. 10(11), 3261-3269.

Arianna Palladini, Susan Thrane, Christoph Janitzek, Jessica Pihl, Stine Clemmensen, Willem De Jongh, Thomas Clausen, Giordano Nicoletti, Lorena Landuzzi, Manuel Penichet, Tania Balboni, Marianna Ianzano, Veronica Giusti, Thor Theander, Morten Nielsen, Ali Salanti, Pier-Luigi Lollini, Patrizia Nanni, Adam Sander (2018) Virus-like particle display of HER2 induces potent anti-cancer responses. 7(3), e1408749.

C Dale, Scott Thomson, Robert De Rose, Charani Ranasinghe, C Medveczky, Joko Pamungkas, David Boyle, Ian Ramshaw, Stephen Kent (2006) Prime-Boost Strategies in DNA Vaccines. 127, 171-198.

Bo Xiang, Trevor Baybutt, Lisa Berman-Booty, Michael Magee, Scott Waldman, Vitali Alexeev, Adam Snook (2017) Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. 198(9), 3507-3514.

Paweł Kawalec, Anna Paszulewicz, Przemysław Holko, Andrzej Pilc (2012) Systematic review/Meta-analysis Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. 5(5), 767-775.

Christopher Pannucci, Edwin Wilkins (2011) Identifying and Avoiding Bias in Research. 126(2), 619-625.

Michael Mahoney (1977) Publication prejudices: An experimental study of confirmatory bias in the peer review system. 1(2), 161-175.

Roman Anton (2017) Falseness in the miRNA-field as an indicator of strategic bias in the research system via peer-review and publishing eligibility. 4(3), 1-10.

Hannah Rothstein, Alexander Sutton, Michael Borenstein (2005) Publication Bias in Meta‐Analysis. 1-7.

John Ioannidis (2005) Why Most Published Research Findings Are False. 2(8), e124.

Henry Bourne (2013) A fair deal for PhD students and postdocs. 2(2).

Vishwanath Sathyanarayanan, Sattva Neelapu (2015) Cancer immunotherapy: Strategies for personalization and combinatorial approaches. 9(10), 2043-2053.

Irene Moya-Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell (2018) Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). 10, 1-12.